TARS
Tarsus Pharmaceuticals Inc.
Company Overview
| Mkt Cap | $3.08B | Price | $67.96 |
| Volume | 296.39K | Change | -0.31% |
| P/E Ratio | -26.6 | Open | $68.16 |
| Revenue | $183.0M | Prev Close | $68.17 |
| Net Income | $-115.6M | 52W Range | $38.51 - $85.25 |
| Div Yield | N/A | Target | $91.13 |
| Overall | 38 | Value | 40 |
| Quality | 47 | Technical | 27 |
No chart data available
About Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is also developing TP-04 for the treatment of Ocular Rosacea; TP-05 for potential Lyme disease prophylaxis; and community malaria reduction. In addition, the company develops lotilaner active pharmaceutical ingredient (API) to address diseases in human medicine, including eye care and infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
Latest News
Barclays Sticks to Its Buy Rating for Tarsus Pharmaceuticals (TARS)
Analysts’ Top Healthcare Picks: Telix Pharmaceuticals (TLPPF), Tarsus Pharmaceuticals (TARS)
Analysts’ Top Healthcare Picks: Telix Pharmaceuticals (TLPPF), Tarsus Pharmaceuticals (TARS)
Tarsus Pharmaceuticals Adds Industry Veteran to Board
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | TARS | $67.96 | -0.3% | 296.39K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Tarsus Pharmaceuticals Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW